Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
G Ital Med Lav Ergon ; 25 Suppl(3): 131-2, 2003.
Article in Italian | MEDLINE | ID: mdl-14979115

ABSTRACT

A study carried out on the mortality of over 3700 individuals who worked in a factory making railway rolling stock, in which crocidolite was used to insulate the coaches from the end of 50's to the end of 70's, was summarized. The clinical data, checked by best evidence method, show that the pleural plaques on HRCT are the best indicator of past asbestos exposure rather than asbestos bodies or free asbestos fibers in BAL.


Subject(s)
Asbestos/toxicity , Occupational Exposure/adverse effects , Humans , Italy , Occupational Medicine/standards , Population Surveillance
2.
Tumori ; 78(1): 32-4, 1992 Feb 29.
Article in English | MEDLINE | ID: mdl-1609456

ABSTRACT

The combination of folinic acid (FA) and 5-fluorouracil (5FU) is the most active systemic chemotherapy against advanced colorectal cancer. Experimental and clinical studies have suggested that the activity of 5FU can be improved by the addition of alpha-interferon (IFN). To evaluate the possibility of a double modulation of 5FU, a pilot study was conducted in the period July 1989-December 1989 with the following regimen: FA (200 mg/m2 i.v. bolus x 5 days) + 5FU (400 mg/m2 i.v. in 15 min x 5 days) + alpha-2b IFN (10 x 10(6) IU subcutaneously on alternate days). FA and 5FU administrations were repeated every 28 days; IFN was administered every week. In the 16 treated patients, 4 partial responses, 4 no changes, and 8 with progression of disease were observed, with an objective response rate of 25% (95% CI, 7.8%-55.1%). Median duration of response was 9.5 months, as was overall survival. Toxicity (fever, fatigue, neurotoxicity, stomatitis and diarrhea) was considerable and led to a reduction in IFN doses in 10/16 patients. Due to the unfavorable cost/benefit ratio, the study was closed and a new trial, with different doses and schedule of IFN, was started within the GISCAD (Italian Group for the Study of Digestive Tract Cancer).


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Colorectal Neoplasms/drug therapy , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/economics , Colorectal Neoplasms/economics , Colorectal Neoplasms/mortality , Cost-Benefit Analysis , Fluorouracil/administration & dosage , Fluorouracil/adverse effects , Fluorouracil/economics , Humans , Interferon alpha-2 , Interferon-alpha/administration & dosage , Interferon-alpha/adverse effects , Leucovorin/administration & dosage , Leucovorin/adverse effects , Recombinant Proteins , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...